Back to Search
Start Over
Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer.
- Source :
- Cancer Science; Oct2014, Vol. 105 Issue 10, p1321-1326, 6p
- Publication Year :
- 2014
-
Abstract
- The FOLFIRINOX combination of chemotherapy drugs had not been fully evaluated for Japanese pancreatic cancer patients. Therefore, we carried out a phase II study to examine the efficacy and safety of FOLFIRINOX in chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. FOLFIRINOX (i.v. infusion of 85 mg/m<superscript>2</superscript> oxaliplatin, 180 mg/m<superscript>2</superscript> irinotecan, and 200 mg/m<superscript>2</superscript> l-leucovorin, followed by a bolus of 400 mg/m<superscript>2</superscript> fluorouracil and a 46-h continuous infusion of 2400 mg/m<superscript>2</superscript> fluorouracil) was given every 2 weeks. The primary endpoint was the response rate. The 36 enrolled patients received a median of eight (range, 1-25) treatment cycles. The response rate was 38.9% (95% confidence interval [ CI], 23.1-56.5); median overall survival, 10.7 months (95% CI, 6.9-13.2); and median progression-free survival, 5.6 months (95% CI, 3.0-7.8). Major grade 3 or 4 toxicities included neutropenia (77.8%), febrile neutropenia (22.2%), thrombocytopenia (11.1%), anemia (11.1%), anorexia (11.1%), diarrhea (8.3%), nausea (8.3%), elevated alanine aminotransferase levels (8.3%), and peripheral sensory neuropathy (5.6%). Febrile neutropenia occurred only during the first cycle. There were no treatment-related deaths. FOLFIRINOX can be a standard regimen showing favorable efficacy and acceptable toxicity profile in chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 13479032
- Volume :
- 105
- Issue :
- 10
- Database :
- Complementary Index
- Journal :
- Cancer Science
- Publication Type :
- Academic Journal
- Accession number :
- 99008751
- Full Text :
- https://doi.org/10.1111/cas.12501